Lone Ottesen named Adcendo CMO

Adcendo, a Danish biotech focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, has appointed Lone Ottesen its chief medical officer (CMO).

Dr Ottesen has extensive global clinical development experience across oncology and immuno-oncology, with a track record of more than 20 years in both early- and late-phase clinical development.

She has held roles of increasing seniority in global oncology development at GSK (LSE: GSK), Eisai (TYO: 4523) and most recently at AstraZeneca (LSE: AZN), where she was global clinical head in late-stage clinical development.